SKYE

Skye Bioscience, Inc.

8.05 USD
-0.35 (-4.17%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Skye Bioscience, Inc. stock is down -34.55% since 30 days ago. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 June’s closed higher than May. 100% of analysts rate it a buy.

About Skye Bioscience, Inc.

Skye Bioscience, Inc. discovers, develops, and commercializes cannabinoid-based molecules. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.

  • Cantor Fitzgerald
    Tue Jun 18, 10:15
    buy
    confirm
  • Cantor Fitzgerald
    Mon Jun 17, 13:32
    buy
    confirm